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multicenter, prospective observational study was performed. Patients who met inclu-
sion criteria were followed-up for a period of 12 months, with 3 visits programmed 
at baseline, 6 months and 12 months. a total of 9 Spanish hospitals were involved in 
the study. Questionnaires used to measure quality of life were: EQ-5D (generic ques-
tionnaire), Minessotta living with heart failure- MLWHF (speciﬁ c questionnaire) and 
Barthel Index (index of independence). RESULTS: A total of 450 patients were 
included, 76% men, mean age was 62.6 years. 66.1% were in NYHA class II, 32.7% 
NYHA class III and 1.1% NYHA class IV. Prevalence of ischemic cardiopathy was 
33.5%. 35% of patients had an implantable device (ICD, RCT or pacemaker). Sig-
niﬁ cant differences were observed in Barthel Index’s scores depending on class: class 
I 97.6 ± 6.7 vs. Class III-IV 91.8 ± 14.6. Related to EQ-5D tariffs, individuals in class 
II had a mean value of 0.8407 ± 0.1887 (out of 1), and mean VAS value of 60.6 ± 
17.39 (out of 100). Individuals in NYHA class III or IV had a mean score of 0.6624 
± 0.2848, and mean VAS value of 51.93 ± 17.15 (out of 100). In a MLWHF question-
naire analyses, patients in NYHA class II showed a mean score of 32.52 ± 20.69 while 
patient in NYHA class III-IV showed a mean score of 50.44 ± 18.23. CONCLU-
SIONS: Our ﬁ ndings showed the results from the three questionnaires were generally 
consistent with each other and values reported from other countries in the 
literature.
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OBJECTIVES: To characterize health-related quality of life (HRQoL) in patients with 
pulmonary arterial hypertension (PAH) in relation to persons of similar age and gender 
in the general United States (US) population. METHODS: Data were obtained from 
a large phase III clinical trial in which patients (n = 274) were randomized to sildenaﬁ l 
or placebo for 12 weeks. We characterized HRQoL using responses to the Short 
Form-36 General Health Survey (SF-36) obtained at baseline; the SF-36 addresses eight 
HRQoL domains: physical functioning (PF), role functioning–physical (RP), bodily 
pain (BP), general health (GH), vitality (VT), social functioning (SF), role function-
ing–emotional (RE), and mental health (MH). Values for these eight domains were 
then standardized to US population norms for persons aged 45–54 years (mean age 
of patients in trial was 49 years). RESULTS: A total of 39% and 58% of patients 
were designated at baseline as Functional Class (FC) II and III, respectively (<1% and 
3% were designated as FC I and IV), with 75% women. Standardized mean scores 
were 30.4 for PF, 27.9 for RP, 47.8 for BP, 34.2 for GH, 41.2 for VT, 38.9 for SF, 
34.9 for RE, and 43.7 for MH. In comparison with the US population, whose mean 
score for each domain = 50, PF, RP, GH, SF, and RE were all substantially worse for 
PAH patients. Additionally MH and VT were marginally worse among PAH patients, 
and BP was comparable to US norms. CONCLUSIONS: With the exception of bodily 
pain and mental health, PAH patients have substantially poorer SF-36 scores than 
their peers in the US general population, especially in terms of physical functioning, 
role functioning-physical, role functioning-emotional, and general health.
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OBJECTIVES: The aim of the present study was to evaluate the effect of 700 mg and 
1400 mg pomegranate seed capsules on body weight and blood pressure for a period 
of 60 days at time interval 7, 14, 21, 28, 45 and 60 days respectively. METHODS: 
At the beginning of the study twenty four healthy human volunteers were selected. 
On the basis of BMI two broader groups, i.e. group 1 taking 700 mg pomegranate 
capsules and group 2 taking 1400 mg pomegranate capsules were designated and both 
the groups were subdivided on the basis of diet control and exercise i.e. group1 (IA, 
IB) and group 2(IIA, IIB). Group IA and IIA took pomegranate capsules without diet 
and exercise while IB and IIB took the capsules with diet and exercise. Hypertensive 
patients from these groups were included in both groups who were categorized and 
evaluated separately and compared with normal individuals. RESULTS: The result of 
investigation indicated that both doses of pomegranate seeds capsules had signiﬁ cantly 
reduced the body weight and blood pressure proﬁ le (both systolic and diastolic) in all 
groups when compared with their baseline values. However both doses caused equal 
reduction of body weight and blood pressure as no signiﬁ cant difference was present 
in both doses (p-value > 0.05). CONCLUSIONS: Thus on the basis of results obtained 
after conducting our study it was concluded that pomegranate seed capsules have 
established their efﬁ cacy and safety proﬁ le for obesity control and hypertension 
management.
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OBJECTIVES: To measure how VKA’s patients assess their treatment in terms of 
medication intake constraints, monitoring and psychological impact related to per-
ceived risk. METHODS: Questionnaires to patients under VKAs for at least 3 months. 
Questionnaires were distributed through 150 retail pharmacies spread over all France 
from November 2009 to March 2010. a random distribution of questionnaire was 
made. RESULTS: 1094 questionnaires were administered. Study included 58% men 
and 42% women aged >65 years for 72%; patients aged more than 75 years repre-
sented 43%. Patients were treated in majority by ﬂ uindione (82.3%) and for more 
than 3 years (65.1%). Patients were treated in majority for cardiac rhythm disorder 
(40%). More than ¾ (77%) of VKAs patients consider their treatment being a burden 
even though being vital. Treatment is judged as being a constraint because of the 
obligation to adapt dosages according to coagulation monitoring (42%), and due to 
the necessity to contact their physician after each blood sample (25%). The require-
ment to permanently have a monitoring is considered as constantly reminding the 
associated risk (65%), expectation of coagulation monitoring results generate anxiety 
for more than ¼ of patients (27%). Majority of patients acknowledge that regular 
blood sampling is a constraint (53%) and that the treatment would be more conve-
nient without these constant blood samplings (60%). In parallel, 38% of patients 
interviewed consider that the VKA treatment constraint is reinforced by the fact that 
they cannot eat what they would like. Patient preference for a new treatment is in 
priority: a treatment without regular blood sampling (62%); a treatment for which 
the daily anticoagulant dosage does not need adaptation (60%). CONCLUSIONS: 
Treatment by VKAs is perceived as burdensome and risky by a majority of patients 
due to the constant monitoring required and the uncertainty of the good blood dosage. 
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OBJECTIVES: While hypertension treatment guidelines emphasize the medical ben-
eﬁ ts of combined medication choice, consumption patterns of antihypertensive drugs 
raise worldwide several questions related to real-life therapeutic and cost-effectiveness. 
Hungary has a relatively poor track record: international comparative studies show 
Hungarian patients’ adherence to treatment to fall behind not only desirable targets 
but also international average values. In our analysis, we start from the hypothesis 
that medical beneﬁ ts achievable through combined therapy are weakened through 
inadequate patient adherence, and we investigate into the health loss caused to Hun-
garian patients by insufﬁ cient persistence in combined hypertension therapy. Our goal 
is to determine how the real-life consumption patterns of combination hypertension 
therapy impact real-life therapeutic effectiveness and cost-effectiveness. METHODS: 
We use itemized prescription-level data from the Hungarian National Health Insur-
ance Fund Administration’s (NHIFA) database. Our research covers patients whose 
therapy was initiated during 2008 or 2009 with high-value ﬁ x-dosage (one-pill) and 
non-ﬁ x-dosage (multiple-pill) angiotensin-converting enzyme inhibitor (ACEI) and 
calcium channel blocker (CCB) combinations, or angiotensin-receptor blocker (ARB) 
and CCB combinations. RESULTS: Adherence to treatment is measured as persistence 
on the initiating combination therapy. Firstly, ‘hard’ persistence (which does not allow 
for add-on therapies) and ‘add-on’ persistence (which allows for additional active 
substances being added to the therapy regime) are separately calculated, both for ﬁ x-
dosage and non-ﬁ x-dosage combinations. Secondly, if the initiating therapy is a ﬁ x-
dosage combination, parallel consumption of monocomponents is also analyzed. 
Thirdly, we carry out a switch analysis to determine the active substances that patients 
had been taking before receiving a ﬁ x-dosage combination, or take after abandoning 
the ﬁ x dosage combined therapy. CONCLUSIONS: We hypothesize that substantial 
societal loss is caused by patient non-adherence in hypertension treatment and clinical 
advantages of combination therapies are signiﬁ cantly impaired. Our research will 
deliver exact calculations for the extent of the societal loss.
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OBJECTIVES: Cardiovascular risk factors remain poorly controlled across Europe 
despite clinical guidelines. The European Study on Cardiovascular Risk Prevention 
and Management in Daily Practice (EURIKA) investigated the use of cardiovascular 
risk assessments tools and guidelines, and explored factors limiting their use. 
METHODS: Physicians (n = 806) from 12 European countries answered questions 
regarding their work setting, their assessment of patients with cardiovascular risk 
factors, and their use of risk calculation tools and clinical guidelines. RESULTS: 
Participating physicians worked in primary care centres or outpatient clinics; 63.8% 
were GPs. The majority (69.3%) reported using global risk calculation tools. Written 
charts were the preferred method (69.9%), followed by software (33.0%). The most 
popular tools were SCORE (European Society of Cardiology [ESC]; 52.4%), 
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Framingham (16.9%) and the European Hypertension Chart (31.3%). Reasons for 
not using risk tools included time constraints (60.8%), not being convinced of their 
utility (22.1%) and lack of knowledge (20.0%). a high percentage of physicians 
believed the algorithms have limitations (72.4%); 92.1% believed they lead to over-
looking other risk factors and 69.3% believed they cannot be used to calculate risk 
in elderly patients. The most commonly used clinical guidelines were those from the 
ESC (CVD Prevention in Clinical Practice [56.3%] and Management of Arterial 
Hypertension [29.9%]) or from local authorities (17%). In total, 12.9% of physicians 
reported not using guidelines; reasons included the wide choice or uncertainty of which 
to use (47.5%), time constraints (33.7%), lack of knowledge (27.7%) and a perception 
that they are unrealistic (23.8%). CONCLUSIONS: Time constraints, perceived utility 
and inadequate knowledge were common factors limiting the use of cardiovascular 
risk evaluation tools and assessment guidelines. Better compliance with risk assessment 
tools may reduce the high proportion of patients with poorly managed cardiovascular 
risk factors.
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OBJECTIVES: The Adult Treatment Panel III guidelines suggest that the goal of low-
density lipoprotein cholesterol (LDL-C) in patients with both cardiovascular disease 
and diabetes is <100 mg/dL. Many patients remain poorly controlled despite various 
interventions in primary care, including statin therapy and health behavior modiﬁ ca-
tion. We evaluated the impact of adding a clinical pharmacist intervention to usual 
care on LDL-C control and treatment costs in diabetic cardiac patients. METHODS: 
We prospectively compared a clinical pharmacist intervention in 138 patients with a 
matched control sample of 353 patients receiving usual care in Maccabi Healthcare 
Services (MHS) in Israel. Patients with cardiovascular disease and diabetes and LDL-C 
levels >100 mg/dL were identiﬁ ed from the MHS’s computerized database. The clinical 
pharmacist reviewed patients’ clinical charts and discussed the recommendations to 
improve hyper-lipidemic control with the patients’ primary-care practitioners. The 
recommendations were given every three months for a one-year period. The primary 
clinical endpoint was reaching LDL-C goal. Clinical outcomes and overall treatment 
costs in both groups were evaluated at the end of the study year. RESULTS: During 
the study year, 67% of the patients in the intervention group reached the LDL goal 
vs. only 54% in the control group (p = 0.014). LDL target was reached three months 
earlier in the intervention group as compared with control patients (0.710 year vs. 
0.992 year, respectively; log-rank test: p = 0.015). However, at the end of the study 
year, LDL target was maintained in approximately 50% of patients in both groups. 
Overall treatment costs (physician visits, hospital and emergency room admissions, 
lab tests, medications) were 14% lower in the intervention group and 11% higher in 
the control group as compared to the year prior the intervention. CONCLUSIONS: 
A clinical pharmacist intervention in high-risk patients may result in clinical improve-
ments and lower treatment costs. These results demonstrate the high-value of clinical 
pharmacist involvement in patient treatment.
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OBJECTIVES: To assess management of cardiovascular risk factors (CVRF) in daily 
clinical practice and to identify areas of potential improvement in primary prevention 
of CVD. METHODS: A total 663 patients >50 years of age (59.4 ± 7.6 years; 47.2% 
males) with at least one additional CVRF and 67 physicians (mean age: 40.7 ± 8.6 
years; 82.1% males) were included from Turkey in the multicentre, multinational, 
cross-sectional epidemiological EURIKA study (NCT00882336) conducted across 
Europe. Management and control of classical, emergent and psycho-social CVRF, use 
of CV risk assessment by the physicians as well as barriers for estimating and using 
global cardiovascular risk scores were identiﬁ ed. RESULTS: Total CV risk assessment 
in Turkish patients was stated to be performed by 48.5% of the physicians mostly by 
chart (71.9%) and mainly for an advice on healthy lifestyle (84.4%) and to decide on 
antihypertensive (78.1%) or lipid-lowering treatment (75.0%). Time constraint for 
global CV risk evaluation was the main reason (73.5%) for the lack of assessment 
identiﬁ ed by the physicians. a total of 514 patients (77.5%) were classiﬁ ed to have 
high CV risk by the physicians using a local (7.6%) or the recent European Guidelines 
on Cardiovascular Disease Prevention in Clinical Practice (ESC 2007) (80.0%). 
Although global cardiovascular risk was said to be under control in 75.5% of the 
patients, satisfying control of CV risk factors was evident in only 56.7% while the 
overall percentage of the patients who were aware of their CV risk was 69.5%. 
CONCLUSIONS: Apparently targets deﬁ ned in guidelines are not sufﬁ ciently met and 
there is clear need for better management of high risk patients. Development of better 
structured and more realistic, simple and credible national guidelines adapted to suit 
local medical and economic conditions should be encouraged.
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OBJECTIVES: To analyze the impact of regional measures in the sales of the renin-
angiotensin system antagonists in Spain. METHODS: Regional measures from each 
of the 17 Spanish Autonomous Regions (AR) were identiﬁ ed by searching on health 
services’ websites. a Regional Measurement Scale (RMS) in rational use of drugs 
(RUD) was constructed. Values ranged from 0 to 24 considering the number and the 
speciﬁ city of the applied politics. The 2009 market share of the Angiotensin-II Recep-
tor Antagonists (AIIRA) vs. Angiotensin-Converting Enzyme (ACE) inhibitors was 
analyzed. AR market shares and RMS correlations were calculated. Correlated AR 
Market shares were adjusted according to the values of RMS using a linear regression 
model for the AR with correlation between the RMS and the market shares. The 
decrease in market share on the AIIRA by RMS point was determined by the slope 
coefﬁ cient of the regression (β). RESULTS: Health plans, clinical guidelines, pharma-
cotherapeutic guides, health technology assessments and therapeutic newsletters, pro-
moting the prescription of ACE inhibitors rather than AIIRA, were identiﬁ ed. In 14 
out of 17 AR, the correlation between the RMS and the market shares was statistically 
signiﬁ cant (r = 0.55, p = 0.004). Of these, three AR scored 0, ﬁ ve 1 to 10, four 10 to 
20, and two 22 and 23 points respectively. a 0.52% decline in the market share AIIRA 
was observed for each point in the RMS. The maximum impact observed in the market 
share was 11.96%. Considering that the variability in the AIIRA market share was 
24.1%, half of it was explainable by the establishment of RUD measures. CONCLU-
SIONS: Results support the fact that not only the establishment of regional measures 
is important but also the way they are implemented.
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OBJECTIVES: Interest in cardiovascular diseases (CVD) in patients with schizophre-
nia has recently become growing among psychiatrists due to its documented incre-
mental mortality for these causes. Identiﬁ cation of markers for such disorders seems, 
therefore, reasonable. Serum Protein-C-Reactive (PCR) levels have been determined 
as a marker of inﬂ ammation in individuals with CVD and/or at high risk for develop-
ing it. However, it is unknown the role of this protein in schizophrenics. Thus, the 
goal of this research was to explore the use of PCR as a marker of inﬂ ammation and 
CVD in patients with Schizophrenia. METHODS: A cross-sectional analysis of the 
BSA administrative claim database was conducted including all men and women, >18 
years, with a schizophrenia spectrum disorders (by DSM-IV criteria) diagnosis. PCR 
measurement together with socio-demographics, evolution, medical history, 10-years 
CVD risk (Framingham equation) and biochemistry data was extracted for analysis. 
RESULTS: A total of 705 patients [53.0% men, 48.2 + 15.8 years (mean + SD), 5.9 
+ 3.2 years of evolution, 79.7% on atypical drugs] met criteria for analysis. Mean 
10-year CVD risk was high; 11.9% + 5.7% and mean PCR levels were 2.6 + 2.5 mg/L 
with 30.4% showing values above normal’s (>3 mg/L). Unadjusted PCR slightly cor-
related with CVD risk; r = 0.171, P < 0.001. After adjusting by age, sex, evolution, 
smoking and anti-inﬂ ammatory drugs treatment, PCR was linearly associated with 
10-year CVD risk stratiﬁ ed by its level of risk (low, moderate, high/very high); respec-
tively, 2.3 (95% CI: 2.1–2.5), 3.1 (2.6–3.5) and 3.7 (3.2–4.1) mg/L; F = 13.5, P < 
0.001. Patients with known CVD showed also higher PCR levels; 3.7 (2.9–4.5) vs. 
2.5 (2.4–2.7) mg/L, p = 0.008, and higher probability of values above normal’s; Odds 
Ratio = 4.71 (2.01–11.04), P < 0.001. CONCLUSIONS: High PCR levels (above 
normals) were associated with both known CVD and high/very high 10-year risk of 
CVD event in patients with schizophrenia. Then, PCR might be a marker of inﬂ am-
mation and CVD in this psychiatric disorder.
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OBJECTIVES: There is controversy in the literature regarding the effects of concomi-
tant use of proton-pump inhibitors (PPIs) potentially reducing the clinical effectiveness 
of clopidogrel. Also in question is whether the effect occurs with all PPIs or only 
omeprazole The purpose of this study is to assess the usage of PPIs in combination 
with clopidogrel in Acute Coronary Syndrome (ACS) patients in the primary care 
setting. METHODS: This was a retrospective study using IMS Disease Analyzer 
databases in France, Germany and the UK. These longitudinal patient databases 
provide information from continuing physician and patient interaction on consulta-
tions, diagnoses and treatments within primary care. RESULTS: From April 2008 to 
April 2009, 57% of post-ACS clopidogrel patients also had a PPI prescribed (France 
